Participating Clinical Centers
Clinical Studies
5405: A Phase I Study of Revlimid ® in Combination with Azacitidine in Patients with Advanced Myelodysplastic Syndrome (MDS)
Status: Not recruiting at this time
Summary:
Please Note: The Rare Diseases Clinical Research Network will make every effort to enroll all the patients we can, but we cannot make any guarantees that we will be able to enroll everyone in a particular study who wants to participate.
The purpose of this study is to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of combination therapy with Revlimid ® and Azacitidine in patients with advanced MDS. The secondary purpose of this study is to review the clinical outcomes of patients with advanced MDS to combination therapy with Revlimid ® and Azacitidine.
Target Enrollment:
Up to 36 patients will be enrolled, and must meet the inclusion criteria to be eligible for enrollment into the study. Participants must be at least 18 years of age, have myelodysplastic syndrome, have a life expectancy > 3 months, and have an Eastern Clinical Oncology Group (ECOG) status of 0, 1, or 2.
How to Participate:
In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail. Please use the information below to inquire about participation.
- Cleveland Clinic Foundation, Cleveland, OH
Susan Sunkle
216.445.2119
sunkles@ccf.org- University of California at Los Angeles, Los Angeles, CA
Troy Overfield-Blain
310.794.8075
toverfield@mednet.ucla.edu- H. Lee Moffitt Cancer Center, Tampa, FL
Lynn Tihopu
310.794.0738
Tihopu@mednet.ucla.edu
Join the Contact Registry: Myelodysplastic Syndromes
